Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ditmarsch

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Lancet (London, England)|May 10, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trialAshish Sarraju, Danielle Brennan, Kierstyn Hayden, et al.
Journal of Lipid Research|March 26, 2026
Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL-clearance and regress atherosclerosis on atorvastatin backgroundJosé A Inia, Leo H Zhang, Nanda Keijzer, et al.
American Heart Journal|May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYNStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
The New England Journal of Medicine|May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine|April 17, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine|February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Lancet (London, England)|May 10, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trialAshish Sarraju, Danielle Brennan, Kierstyn Hayden, et al.
Journal of Lipid Research|March 26, 2026
Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL-clearance and regress atherosclerosis on atorvastatin backgroundJosé A Inia, Leo H Zhang, Nanda Keijzer, et al.
American Heart Journal|May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYNStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
The New England Journal of Medicine|May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine|April 17, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine|February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Pageof 4